UPCC 11417: A Phase 3 Multicenter Randomized Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia
Brief description of study
Request for collaborative review: WIRB serving as IRB of record.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Acute Myeloid Leukemia
-
Age: - 99 Years
-
Gender: All
Updated on
30 Jan 2020.
Study ID: 827342